Publication: Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.
No Thumbnail Available
Date
2021-05-01T00:00:00Z
Authors
Authors
Ozguroglu, Mustafa
Sezer, Ahmet
Kilickap, Saadettin
Gumus, Mahmut
Bondarenko, Igor
Gogishvili, Miranda
Turk, Haci M.
Cicin, Irfan
Bentsion, Dmitry
Gladkov, Oleg
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Abstract
Description
Keywords
Citation
Ozguroglu M., Sezer A., Kilickap S., Gumus M., Bondarenko I., Gogishvili M., Turk H. M. , Cicin I., Bentsion D., Gladkov O., et al., -Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.-, JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021